A 1975 meeting at the Asilomar Conference Center in Pacific Grove, California, shaped a new safety regime for recombinant DNA ...

WASHINGTON — Indiana Senator Todd Young testified before the House Armed Services Committee on Tuesday about the growing competition between the U.S. and China in biotechnology. He explained how ...

A U.S. congressional commission has made the case for “swift action” to maintain the nation’s role as a biotech superpower, while warning the sector is “dangerously close to falling behind ...

If India is looking at China for inspiration in the startup ecosystem, then it would be remiss not to also examine China’s strides in the biotechnology sector. The potential for growth and ...

Raigad, Maharashtra. - The Company's major foray into the business of biotechnology based products it was proposed to change the name of the Company from Kopran Drugs Limited to KDL Biotech ...

Few companies embody the term 'pharma giant' as much as Pfizer. Here we take a look at the colourful history of one of the biggest drugmakers in the world. Pfizer was founded in 1849 by two recent ...

Political pressure and persistently high interest rates have some wondering if the industry’s model is broken.

Emerging biotechnology is key for U.S. to remain dominant and secure future economic growth in a new era of global competition. WASHINGTON, April 8, 2025 /PRNewswire/ -- Today, the National ...

EQS Dissemination of Financial Reports: Marinomed Biotech AG / Release of Financial Reports Marinomed Biotech AG: Release of a Financial report 16.04.2025 / 07:45 CET/CEST Announcement according ...

On March 6, Jared Holz, Mizuho health care equity strategist, appeared on CNBC’s ‘Power Lunch’ to discuss investing in biotech and the oversaturation in the sector. He said that looking at ...

AstraZeneca is a company with a turbulent history but, for now ... following its creation was of KuDOS Pharmaceuticals, a UK biotech company, for £120 million in 2005. The same year, AZ also ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech ...